Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs.

Authors: Ainsa J, Amaral L, Couto I, Machado D, Martins M, Rodrigues L, Viveiros M
Journal: Expert Review of Anti-infective Therapy
Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Inhibitors+of+mycobacterial+efflux+pumps+as+potential+boosters+for+anti-tubercular+drugs

Tuberculosis is one of the major causes of infection across the world. The emergence of multi-, extensively- and totally drug-resistant strains of Mycobacterium tuberculosis contributes to the lack of therapeutic options available.
Read More

The in vitro activity of products formed from exposure of chlorpromazine to a 266nm laser beam against species of mycobacteria of human interest

Authors: Alexandru T, Amaral L, Armada AM, Boni M, Danko B, Dinache A, Hunyadi A, Machado D, Molnar J, Nastasa V, Pascu ML, Ramos J, Viveiros M
Publication Year: 2013
Journal: In vivo
Link: http://www.ncbi.nlm.nih.gov/pubmed/23988894

Chlorpromazine (CPZ) was exposed to a 266 nm laser beam for different periods of time ranging from minutes to 24 h. At intervals, the products from irradiation were evaluated by thin-layer chromatography (TLC) and evaluated for their activity against mycobacteria of human interest (Mycobacterium tuberculosis, M. avium, M. intracellulare and their corresponding reference strains or clinical isolates).
Read More

Identification of nontuberculous mycobacteria in clinical samples using molecular methods: a 3-year study

Nontuberculous mycobacteria (NTM) are being increasingly isolated in clinical laboratories and present technical and therapeutic challenges.
Read More

Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy

Authors: Azzali E, Costa SS, Costantino G, Couto I, Machado D, Pieroni M, Viveiros M
Publication Year: 2015
Journal: Journal of Medicinal Chemistry
Link: https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00428

Tuberculosis, caused by Mycobacterium tuberculosis, is still one of the leading infectious diseases globally. Therefore, novel approaches are needed to face this disease. Efflux pumps are known to contribute to the emergence of M. tuberculosis drug resistance. Thioridazine has shown good anti-TB properties both in vitro and in vivo, likely due to its capacity to […]
Read More

Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil

Authors: Coelho T, Couto I, Machado D, Maschmann R, Ramos D, Rossetti ML, Silva PA, Viveiros M, von Groll A
Publication Year: 2015
Journal: Frontiers in Microbiology
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412083/%20

Drug resistant tuberculosis continues to increase and new approaches for its treatment are necessary. The identification of M. tuberculosis clinical isolates presenting efflux as part of their resistant phenotype has a major impact in tuberculosis treatment. In this work, we used a checkerboard procedure combined with the tetrazolium microplate-based assay (TEMA) to study single combinations […]
Read More

Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs.

The in vitro activity of products formed from exposure of chlorpromazine to a 266nm laser beam against species of mycobacteria of human interest

Identification of nontuberculous mycobacteria in clinical samples using molecular methods: a 3-year study

Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy

Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil

About GHTM

Contacts

Funding